Loading
A phase 3 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by National Cancer Institute (NCI), active but no longer recruiting.
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor is a phase 3, randomised interventional study registered as NCT00569127 by National Cancer Institute (NCI), with a registry enrolment figure of 427 participants, started 2007-12-01 and due to reach its primary completion in 2015-01-01. Interventions recorded: Bevacizumab; Laboratory Biomarker Analysis; Octreotide Acetate; Recombinant Interferon Alfa-2b. Conditions listed: Colorectal Neuroendocrine Tumor G1; Gastric Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2. Primary outcome: Central Review-based Progression-Free Survival. Colorectal eligibility wording from the registry: "* Metastatic colorectal carcinoid; patients with metastatic cecal or appendiceal carcinoid tumor are not eligible unless the tumors fit into one of the other high-risk categories (a, b, or c above)". Sites: United States. Results were posted on ClinicalTrials.gov in 2016; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
427 enrolled.
95% CI 12.9 to 19.6; Figures from the ClinicalTrials.gov results section (first posted 2016-04-28), not from a publication · 95% CI 9.6 to 18.6
Source95% CI 33.1 to 42.8; Figures from the ClinicalTrials.gov results section (first posted 2016-04-28), not from a publication · 95% CI 35.8 to 52.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Central Review-based Progression-Free Survivalprimary | Octreotide, Bevacizumab | 200 | 16.6 months | 0.93 (0.73 to 1.18) | 0.55 | link |
| Octreotide, Interferon Alpha-2b | 202 | 15.4 months | ||||
| Overall Survival | Octreotide, Bevacizumab | 200 | 35.2 months | - | - | link |
| Octreotide, Interferon Alpha-2b | 202 | 47.3 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/